retatrutide type 2 diabetes phase 2 results 2024 ada 🩺 in diabetes: TRANSCEND-T2D-1 3 → HbA1c ↓2.0% + weight ↓16.8% at 40 weeks. A triple agonist that tackles both glycemia and obesity simultaneously. 📊💊 Ref: Lilly Phase 2 trial results demonstrate

Ready to Get Started

Retatrutides effects on the pancreas and thyroid are under scrutiny, as preclinical studies of similar GLP-1 receptor agonists have raised questions about pancreatitis and thyroid C-cell abnormalities

Both medications affect gastric motility and liver metabolism, which can alter alcohol tolerance

Additionally, pancreatic cancer can itself cause diabetes (reverse causality), making it difficult to determine whether any observed increase in cancer incidence is attributable to the medication or the underlying metabolic condition

One molecule

the synergistic action of both of these hormones may, therefore, produce a desirable net effect on nutrient anabolism/catabolism